Tryp Therapeutics (TRYP) | WebDisclosure

Switch to English

8296	Sociétés
114905	Mots-clés
55332	Articles
62461	Communiqués

Accueil
Sociétés
Tryp Therapeutics

BRÈVE

publiée le 01/05/2024 à 21:23, il y a 6 mois 19 jours

Tryp Therapeutics finalise son acquisition par Exopharm Limited

Transaction Boursière Bourse Des Valeurs Canadiennes Tryp Thérapeutique Exopharm Limitée Bourse Australienne Des Valeurs Mobilières
BRÈVE

publiée le 01/05/2024 à 21:23, il y a 6 mois 19 jours

Tryp Therapeutics Completes Acquisition by Exopharm Limited

Tryp Therapeutics Canadian Securities Exchange Exopharm Limited Stock Transaction Australian Securities Exchange
COMMUNIQUÉ DE PRESSE

publié le 01/05/2024 à 21:18, il y a 6 mois 19 jours

Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
Tryp Therapeutics, Inc. and Exopharm Limited announce completion of acquisition deal through court-approved plan of arrangement. Shareholders to receive 3.616 Exopharm Shares for each Tryp Share held

Shareholders Tryp Therapeutics Exopharm Limited Arrangement Agreement Acquisition Deal
BRÈVE

publiée le 24/04/2024 à 12:05, il y a 6 mois 27 jours

Tryp Therapeutics Gears Up for Merger Completion with Exopharm, Announces Trading Halt

Tryp Therapeutics Exopharm Limited Mergers And Acquisitions Stock Trading Halt ASX Listing
BRÈVE

publiée le 24/04/2024 à 12:05, il y a 6 mois 27 jours

Tryp Therapeutics se prépare à finaliser sa fusion avec Exopharm et annonce l'arrêt des négociations

Fusions Et Acquisitions Tryp Thérapeutique Exopharm Limitée Arrêt Des Opérations Boursières Inscription ASX
COMMUNIQUÉ DE PRESSE

publié le 24/04/2024 à 12:00, il y a 6 mois 27 jours

Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Tryp Therapeutics, Inc. announces shareholder approval and completion of plan of arrangement with Exopharm Limited. Anticipates trading on ASX as Tryptamine Therapeutics Limited (ticker symbol TYP) in May 2024

Shareholder Approval Exopharm Limited Plan Of Arrangement Tryp Therapeutics Inc. ASX Trading
BRÈVE

publiée le 12/03/2024 à 11:05, il y a 8 mois 9 jours

Tryp Therapeutics Announces Overwhelming Shareholder Approval for Arrangement Agreement

Biotechnology Tryp Therapeutics Shareholder Approval Exopharm Limited Arrangement Agreement
BRÈVE

publiée le 12/03/2024 à 11:05, il y a 8 mois 9 jours

Tryp Therapeutics annonce l'approbation massive des actionnaires pour la convention d'arrangement

Biotechnologie Approbation Des Actionnaires Tryp Thérapeutique Accord D'arrangement Exopharm Limitée
COMMUNIQUÉ DE PRESSE

publié le 12/03/2024 à 11:00, il y a 8 mois 9 jours

Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Tryp Therapeutics announces securityholders' approval of Arrangement with Exopharm Limited CAN 163 765 991 at annual meeting. Closing expected in late March 2024

Tryp Therapeutics Exopharm Limited Securityholders Arrangement Clinical-stage Biotechnology
COMMUNIQUÉ DE PRESSE

publié le 08/02/2024 à 22:00, il y a 9 mois 12 jours

Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics, Inc. obtains interim court order for proposed arrangement with Exopharm Limited ACN 163 765 991. Meeting scheduled for March 8, 2024, in Toronto, Ontario, to vote on the arrangement resolution

Tryp Therapeutics Exopharm Limited Interim Court Order Arrangement Resolution Meeting

Les Echos

Publié le 21/11/2024 à 06:58, il y a 6 heures 54 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 54 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 54 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 45 minutes

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 32 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 13:30, il y a 22 minutes

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 22 minutes

Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 52 minutes

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 52 minutes

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 52 minutes

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 13:41, il y a 11 minutes

Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 13:15, il y a 37 minutes

NOTICE OF ANNUAL GENERAL MEETING
Publié le 21/11/2024 à 12:35, il y a 1 heure 17 minutes

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 37 minutes

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Publié le 21/11/2024 à 12:06, il y a 1 heure 46 minutes

IVU AG publishes Quarterly Report Q3-2024